Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Combined Vaccination with NY-ESO-1 Protein, Poly-ICLC, and Montanide Improves Humoral and Cellular Immune Responses in Patients with High-Risk Melanoma.

Pavlick A, Blazquez AB, Meseck M, Lattanzi M, Ott PA, Marron TU, Holman RM, Mandeli J, Salazar AM, McClain CB, Gimenez G, Balan S, Gnjatic S, Sabado RL, Bhardwaj N.

Cancer Immunol Res. 2020 Jan;8(1):70-80. doi: 10.1158/2326-6066.CIR-19-0545. Epub 2019 Nov 7.

PMID:
31699709
2.

Poly-ICLC, a TLR3 Agonist, Induces Transient Innate Immune Responses in Patients With Treated HIV-Infection: A Randomized Double-Blinded Placebo Controlled Trial.

Saxena M, Sabado RL, La Mar M, Mohri H, Salazar AM, Dong H, Correa Da Rosa J, Markowitz M, Bhardwaj N, Miller E.

Front Immunol. 2019 Apr 9;10:725. doi: 10.3389/fimmu.2019.00725. eCollection 2019.

3.

Adjuvant NY-ESO-1 vaccine immunotherapy in high-risk resected melanoma: a retrospective cohort analysis.

Lattanzi M, Han J, Moran U, Utter K, Tchack J, Sabado RL, Berman R, Shapiro R, Huang HH, Osman I, Bhardwaj N, Pavlick AC.

J Immunother Cancer. 2018 May 18;6(1):38. doi: 10.1186/s40425-018-0345-7.

4.

Dendritic cell-based immunotherapy.

Sabado RL, Balan S, Bhardwaj N.

Cell Res. 2017 Jan;27(1):74-95. doi: 10.1038/cr.2016.157. Epub 2016 Dec 27. Review.

5.

Dendritic Cell Vaccines.

Sabado RL, Meseck M, Bhardwaj N.

Methods Mol Biol. 2016;1403:763-77. doi: 10.1007/978-1-4939-3387-7_44.

PMID:
27076166
6.

Cancer immunotherapy: dendritic-cell vaccines on the move.

Sabado RL, Bhardwaj N.

Nature. 2015 Mar 19;519(7543):300-1. doi: 10.1038/nature14211. Epub 2015 Mar 11. No abstract available.

PMID:
25762139
7.

Resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with high-risk melanoma.

Sabado RL, Pavlick A, Gnjatic S, Cruz CM, Vengco I, Hasan F, Spadaccia M, Darvishian F, Chiriboga L, Holman RM, Escalon J, Muren C, Escano C, Yepes E, Sharpe D, Vasilakos JP, Rolnitzsky L, Goldberg J, Mandeli J, Adams S, Jungbluth A, Pan L, Venhaus R, Ott PA, Bhardwaj N.

Cancer Immunol Res. 2015 Mar;3(3):278-287. doi: 10.1158/2326-6066.CIR-14-0202. Epub 2015 Jan 29.

8.

MAGE-specific T cells detected directly ex-vivo correlate with complete remission in metastatic breast cancer patients after sequential immune-endocrine therapy.

Janosky M, Sabado RL, Cruz C, Vengco I, Hasan F, Winer A, Moy L, Adams S.

J Immunother Cancer. 2014 Sep 16;2(1):32. doi: 10.1186/s40425-014-0032-2.

9.

Preparation of tumor antigen-loaded mature dendritic cells for immunotherapy.

Sabado RL, Miller E, Spadaccia M, Vengco I, Hasan F, Bhardwaj N.

J Vis Exp. 2013 Aug 1;(78). doi: 10.3791/50085.

10.

Dendritic cell immunotherapy.

Sabado RL, Bhardwaj N.

Ann N Y Acad Sci. 2013 May;1284:31-45. doi: 10.1111/nyas.12125.

PMID:
23651191
11.

Spatiotemporal trafficking of HIV in human plasmacytoid dendritic cells defines a persistently IFN-α-producing and partially matured phenotype.

O'Brien M, Manches O, Sabado RL, Baranda SJ, Wang Y, Marie I, Rolnitzky L, Markowitz M, Margolis DM, Levy D, Bhardwaj N.

J Clin Invest. 2011 Mar;121(3):1088-101. doi: 10.1172/JCI44960. Epub 2011 Feb 21.

12.

Evidence of dysregulation of dendritic cells in primary HIV infection.

Sabado RL, O'Brien M, Subedi A, Qin L, Hu N, Taylor E, Dibben O, Stacey A, Fellay J, Shianna KV, Siegal F, Shodell M, Shah K, Larsson M, Lifson J, Nadas A, Marmor M, Hutt R, Margolis D, Garmon D, Markowitz M, Valentine F, Borrow P, Bhardwaj N.

Blood. 2010 Nov 11;116(19):3839-52. doi: 10.1182/blood-2010-03-273763. Epub 2010 Aug 6.

13.

Directing dendritic cell immunotherapy towards successful cancer treatment.

Sabado RL, Bhardwaj N.

Immunotherapy. 2010 Jan;2(1):37-56. doi: 10.2217/imt.09.43. Review.

14.

HIV-1 impairs in vitro priming of naïve T cells and gives rise to contact-dependent suppressor T cells.

Che KF, Sabado RL, Shankar EM, Tjomsland V, Messmer D, Bhardwaj N, Lifson JD, Larsson M.

Eur J Immunol. 2010 Aug;40(8):2248-58. doi: 10.1002/eji.201040377.

15.

Pathways utilized by dendritic cells for binding, uptake, processing and presentation of antigens derived from HIV-1.

Sabado RL, Babcock E, Kavanagh DG, Tjomsland V, Walker BD, Lifson JD, Bhardwaj N, Larsson M.

Eur J Immunol. 2007 Jul;37(7):1752-63.

16.

Genetic and stochastic influences on the interaction of human immunodeficiency virus type 1 and cytotoxic T lymphocytes in identical twins.

Yang OO, Church J, Kitchen CM, Kilpatrick R, Ali A, Geng Y, Killian MS, Sabado RL, Ng H, Suen J, Bryson Y, Jamieson BD, Krogstad P.

J Virol. 2005 Dec;79(24):15368-75.

17.

Clonal breadth of the HIV-1-specific T-cell receptor repertoire in vivo as determined by subtractive analysis.

Killian MS, Sabado RL, Kilpatrick S, Hausner MA, Jamieson BD, Yang OO.

AIDS. 2005 Jun 10;19(9):887-96.

PMID:
15905669
18.

Detection of HIV-1-specific CTL responses in Clade B infection with Clade C Peptides and not Clade B consensus peptides.

Sabado RL, Kilpatrick S, Ali A, Dagarag M, Ng HL, Cao H, Yang OO.

J Immunol Methods. 2005 Jan;296(1-2):1-10. Epub 2004 Nov 19.

PMID:
15680145

Supplemental Content

Loading ...
Support Center